PharmaVoice
Foghorn's CEO on why collaborations are key to unlocking precision medicine
January 28, 2022
FierceBiotech
Eli Lilly puts $1.3B in biobucks on the line for Foghorn's oncology programs
December 13, 2021
Endpoints
Eli Lilly's Van Naarden hands $380M cash to Flagship-backed upstart in major new oncology deal
December 13, 2021
MedCityNews
Eli Lilly steers into Foghorn’s gene traffic control drugs with $380M pact in cancer
December 13, 2021
BioSpace
Q&A: Foghorn SVP Expounds on "Tremendous Opportunity" in Chromatin Remodeling
April 20, 2021
